GB0024361D0 - Medicaments - Google Patents

Medicaments

Info

Publication number
GB0024361D0
GB0024361D0 GBGB0024361.8A GB0024361A GB0024361D0 GB 0024361 D0 GB0024361 D0 GB 0024361D0 GB 0024361 A GB0024361 A GB 0024361A GB 0024361 D0 GB0024361 D0 GB 0024361D0
Authority
GB
United Kingdom
Prior art keywords
methyl
medicaments
sulfanyl
thiazol
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0024361.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0024361.8A priority Critical patent/GB0024361D0/en
Publication of GB0024361D0 publication Critical patent/GB0024361D0/en
Priority to ES01972266T priority patent/ES2259675T3/es
Priority to JP2002532258A priority patent/JP4106263B2/ja
Priority to EP01972266A priority patent/EP1324774B1/en
Priority to AT01972266T priority patent/ATE318615T1/de
Priority to AU2001292046A priority patent/AU2001292046A1/en
Priority to US10/398,629 priority patent/US7084161B2/en
Priority to DE60117584T priority patent/DE60117584T2/de
Priority to PCT/GB2001/004373 priority patent/WO2002028434A2/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
GBGB0024361.8A 2000-10-05 2000-10-05 Medicaments Ceased GB0024361D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB0024361.8A GB0024361D0 (en) 2000-10-05 2000-10-05 Medicaments
ES01972266T ES2259675T3 (es) 2000-10-05 2001-10-01 Uso de un activador de ppar delta para el tratamiento de afecciones inflamatorias.
JP2002532258A JP4106263B2 (ja) 2000-10-05 2001-10-01 炎症性の状態の治療のためのｐｐａｒデルタ活性化因子の使用
EP01972266A EP1324774B1 (en) 2000-10-05 2001-10-01 Use of a ppar delta activator for treating inflammatory conditions
AT01972266T ATE318615T1 (de) 2000-10-05 2001-10-01 Verwendung von einem ppar delta aktivator zur behandlung von entzündlichen zuständen
AU2001292046A AU2001292046A1 (en) 2000-10-05 2001-10-01 Use of a ppar delta activator for treating inflammatory conditions
US10/398,629 US7084161B2 (en) 2000-10-05 2001-10-01 Method for treating inflammatory diseases or conditions
DE60117584T DE60117584T2 (de) 2000-10-05 2001-10-01 Verwendung von einem ppar-delta aktivator zur behandlung von entzündlichen zuständen
PCT/GB2001/004373 WO2002028434A2 (en) 2000-10-05 2001-10-01 Use of a ppar delta activator for treating inflammatory conditions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0024361.8A GB0024361D0 (en) 2000-10-05 2000-10-05 Medicaments

Publications (1)

Publication Number Publication Date
GB0024361D0 true GB0024361D0 (en) 2000-11-22

Family

ID=9900709

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0024361.8A Ceased GB0024361D0 (en) 2000-10-05 2000-10-05 Medicaments

Country Status (9)

Country Link
US (1) US7084161B2 (https=)
EP (1) EP1324774B1 (https=)
JP (1) JP4106263B2 (https=)
AT (1) ATE318615T1 (https=)
AU (1) AU2001292046A1 (https=)
DE (1) DE60117584T2 (https=)
ES (1) ES2259675T3 (https=)
GB (1) GB0024361D0 (https=)
WO (1) WO2002028434A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1357914A2 (en) * 2001-02-02 2003-11-05 SmithKline Beecham Corporation Treatment of ppar mediated diseases
CA2449247A1 (en) * 2001-06-11 2002-12-19 Merck & Co., Inc. A method for treating inflammatory diseases by administering a ppar-delta agonist
EP1435946B8 (en) 2001-09-14 2013-12-18 Amgen Inc. Linked biaryl compounds
FR2836829B1 (fr) * 2002-03-11 2005-11-25 Bio Merieux Utilisation de l-alpha-lysophosphatidylcholine pour obtenir la differenciation de monocytes en cellules dendritiques matures in vitro
WO2005097098A2 (en) * 2004-04-01 2005-10-20 Aventis Pharmaceuticals Inc. Use of ppr delta agonists for treating demyelinating diseases
DE602005024384D1 (de) 2004-05-05 2010-12-09 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
WO2006020830A2 (en) 2004-08-12 2006-02-23 Amgen Inc. Bisaryl-sulfonamides
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
CN103224477A (zh) 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
US20080004281A1 (en) * 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
US8802705B2 (en) * 2007-05-21 2014-08-12 Senju Pharmaceutical Co., Ltd. Pharmaceutical containing PPAR delta agonist
AU2010282399A1 (en) * 2009-08-14 2012-03-01 Cerenis Therapeutics Holding S.A. Use of PPAR delta ligands for the treatment or prevention of inflammation or energy metabolism/production related diseases
KR102038866B1 (ko) * 2012-12-24 2019-10-31 서울대학교산학협력단 ＰＰＡＲδ 활성물질의 항생제, 화상 및 창상 치료제, 당뇨성 족부궤양 치료제로서의 용도
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
KR102750722B1 (ko) * 2022-03-16 2025-01-09 재단법인 대구경북첨단의료산업진흥재단 싸이아다이아졸 화합물 및 이를 포함하는 염증성 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
AU8355998A (en) * 1997-07-24 1999-02-16 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
EP1324774A2 (en) 2003-07-09
AU2001292046A1 (en) 2002-04-15
DE60117584D1 (de) 2006-04-27
US7084161B2 (en) 2006-08-01
DE60117584T2 (de) 2006-12-21
EP1324774B1 (en) 2006-03-01
ATE318615T1 (de) 2006-03-15
JP4106263B2 (ja) 2008-06-25
US20050131035A1 (en) 2005-06-16
ES2259675T3 (es) 2006-10-16
JP2004510750A (ja) 2004-04-08
WO2002028434A3 (en) 2002-08-15
WO2002028434A2 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
GB0024361D0 (en) Medicaments
DK1223980T3 (da) Anvendelse af CSF-1-inhibitorer
WO2001081312A3 (en) Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
ATE50256T1 (de) Hypoglycemische thiazolidinedione.
RU2005108133A (ru) Дипептиднитрильные ингибиторы катепсина к
IL182647A0 (en) An oral preparation having improved bioavailability
WO2001085256A3 (en) Critical illness neuropathy
FI973733A0 (fi) Farmaceutiskt preparat och foerfarande foer dess framstaellning
WO2002096318A3 (en) Method for treating glaucoma v
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
NZ530772A (en) 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
CA2530006A1 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
AU2006252214A1 (en) Methods for treating hepatitis delta virus infection with beta-L-2'-deoxy-nucleosides
RU2001131722A (ru) 5-[4-(6-Метокси-1-метил-1Н-бензимидазол-2-илметокси)бензил]-тиазолидин-2,4 -ди он гидрохлорид, обладающий гипогликемической активностью
BR0211329A (pt) Composição farmacêutica de derivados de 4-[(4-tiazolil)-fenoxi]alcoxi-benzamidina para tratamento de osteoporose
DE50201780D1 (de) Halogensubstituierte aminodicarbonsäurederivate als arzneimittel zur behandlung von herz-kreislauf-erkrankungen
AU2001277659A1 (en) Heteropolycyclic inhibitors
AR037164A1 (es) Metodo de tratamiento.
RU2003137576A (ru) Новые гетероциклические производные и их медицинское использование
EP0906755A3 (en) Use of phenyl oxazole or phenyl thiazole derivatives for treating neuropathic pain
EP0908180A3 (en) Use of phenyl oxazole or phenyl thiazole derivatives for treating pain
NO20041378L (no) [[2-(Amino-3,4-diokso-1-cyklobuten-1-yl)amino]alkyl]-syrederivater for behandling av smerte
EP1062948A4 (en) DRUGS AGAINST CARDIAC DIASTOLIC DISORDERS
SE0103509D0 (sv) Rosuvastatin in pre demented states
CO4980892A1 (es) Nuevas formas seudopolimorficas del dihidrocloruro del acido 2-(2-(4-(bis(4-fluorofenil)metil)-1-piperazinil)etoxi)aceti- co

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)